Constitutive expression of IL-12R22 on human multiple myeloma cells delineates a novel therapeutic target

Blood

Volumn 112, Issue 3, 2008, Pages 750-759

  Airoldi, Irma ^a   Cocco, Claudia ^a   Giuliani, Nicola ^b   Ferrarini, Marina ^c   Colla, Simona ^b   Ognio, Emanuela ^d   Taverniti, Giuseppe ^d   Di Carlo, Emma ^e   Cutrona, Giovanna ^d   Perfetti, Vittorio ^f   Rizzoli, Vittorio ^b   Ribatti, Domenico ^g   Pistoia, Vito ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR BETA2; INTERLEUKIN 6; PROTEIN KINASE B; THROMBOCYTE FACTOR 4; TISSUE INHIBITOR OF METALLOPROTEINASE 2; IL12RB2 PROTEIN, HUMAN; INTERLEUKIN 12 RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MOUSE; MOUSE MUTANT; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

AGED; AGED, 80 AND OVER; ANIMALS; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-12; MICE; MICE, SCID; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN-12; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 50949131990     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-139378     Document Type: Article

References (67)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Strobeck M. Multiple myeloma therapies. Nat Rev Drug Discov. 2007;6:181-182.
3. Airoldi I, Di Carlo E, Banelli B, et al. The IL12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest. 2004; 113:1651-1659.
4. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993:178: 1223-1230.
5. Colombo MP, Trinchieri G. Interleukin-12 in antitumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13:155-168.
6. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. J Immunol. 2000:165:2665-2670.
7. Airoldi I, Di Carlo E, Cocco C, et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A. 2007;104: 3996-4001.
8. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer. 1998;78:361-365.
9. Duda DG, Sunamura M, Lozonschi L, et al. Direct in vitro evidence and in vivo analysis of the anti-angiogenesis effects of interleukin 12. Cancer Res. 2000;60:1111-1116.
10. Sgadari C, Angiolillo AL, Tosato G. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 1996;87: 3877-3882.
11. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 1995;87:581-586.
12. Airoldi I, Cocco C, Di Carlo E, et al. Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res. 2006;66:3978-3980.
13. Airoldi I, Di Carlo E, Coceo C, et al. Lack of II12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood. 2005;106: 3846-3853.
14. Lin BT. Weiss LM. Primary plasmacytoma of lymph nodes. Hum Pathol. 1997;28:1083-1090.
15. Roodman GD. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res. 2002;17:1921-1925.
16. Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol. 2003;4:557-564.
17. Durie BG. Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
18. Kuritani T, Cooper MD. Human B cell differentiation: III. Enhancing effect of monoclonal anti-immunoglobulin D antibody on pokeweed mitogen-induced plasma cell differentiation. J Immunol. 1982;129:2490-2495.
19. Kuritani T Cooper MD. Human B cell differentiation: II. Pokeweed mitogen-responsive B cells belong to a surface immunoglobulin D-negative subpopulation. J Exp Med. 1982;155:1561-1566.
20. Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002;100:1113-1122.
21. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science. 2002;298:2199-2202.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408.
23. Airoldi I, Gri G, Marshall JD, et al. Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J Immunol. 2000;165:6880-6888.
24. Ribatti D, Gualandris A, Bastaki M, et al. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res. 1997;34:455-463.
25. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.
26. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006;12:235-239.
27. Hariouche R, Hussain SN. Signaling and regulation of endothelial cell survival by angiopoietin-2. Am J Physiol Heart Circ Physiol. 2006;291:1635-1645.
28. Melani C, Stoppacciaro A, Foroni C, Felicetti F, Care A, Colombo MP. Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis. Cancer Immunol Immunother. 2004;53:600-608.
29. Petrovic N, Schacke W, Gahagan JR, et al. CD13/APN regulates endothelial invasion and filopodia formation. Blood. 2007;110:142-150.
30. Rangel R, Sun Y, Guzman-Rojas L, et al. Impaired angiogenesis in aminopeptidase N-null mice. Proc Natl Acad Sci U S A. 2007;104:4588-4593.
31. Chen J, Lee BH, Williams IR, et al. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005;24:8259-8267.
32. Kertesz N, Krasnoperov V, Reddy R, et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood. 2006;107:2330-2338.
33. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer. 2004;11: 709-724.
34. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 2004; 23:4018-4028.
35. L'Hote CG, Knowles MA. Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res. 2005;304:417-431.
36. Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A. 2004; 101: 5583-5588.
37. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159-178.
38. Takahashi N, Haba A, Matsuno F, Seon BK. Anti-angiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. 2001;61:7846-7854.
39. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis. 2007; 38:258-268.
40. Ren Y, Cao B, Law S, et al. Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res. 2005;11:6190-6197.
41. Yamagishi H, Olson EN, Srivastava D. The basic helix-loop-helix transcription factor, dHAND. is required for vascular development. J Clin Invest. 2000;105:261-270.
42. Towler DA. Vascular biology and bone formation: hints from HIF J Clin Invest. 2007;117:1477-1480.
43. Sakurai D, Tsuchiya N, Yamaguchi A, et al. Crucial role of inhibitor of DNA binding/differentiation in the vascular endothelial growth factor-induced activation and angiogenic processes of human endothelial cells. J Immunol. 2004;173:5801-5809.
44. Eliceiri BP, Cheresh DA. The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999;103:1227-1230.
45. Favier B, Alam A, Barron P, et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cells survival and migration. Blood. 2006:108:1243-1250.
46. Staton CA, Kumar I, Reed MW, Brown NJ. Neuropilins in physiological and pathological angiogenesis. J Pathol. 2007;212:237-248.
47. Sales KJ, Katz AA, Howard B, Soeters RP, Millar RP, Jabbour HN. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 2002;62:424-432.
48. Vinals F, Pouyssegur J. Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol. 2001;21:7218-7230.
49. Uriel S, Brey EM, Greisler HP. Sustained low levels of fibroblast growth factor-1 promote persistent microvascular network formation. Am J Surg. 2006;192:604-609.
50. Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A. 2005;102:2934-2939.
51. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell. 2004; 15:2834-2841.
52. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol. 1996;106:1114-1118.
53. Ozawa S, Shinohara H, Kanayama HO, et al. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha. Neoplasia. 2001;3:154-164.
54. Seo DW, Li H, Guedez L, et al. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell. 2003;114:171-180.
55. Slaton JW, Perrotte P, lnoue K, Dinney CP, Fidler IJ. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Glin Cancer Res. 1999;5:2726-2734.
56. Huston A, Roodman GD. Role of the microenvironment in multiple myeloma bone disease. Future Oncol. 2006;2:371-378.
57. Ribatti D, Nico B, Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene. 2006;25:4257-4266.
58. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20:193-199.
59. Ria R, Roccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia. 2003;17:1961-1966.
60. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol. 2006; 34:1289-1295.
61. Frassanito MA, Cusmai A, Dammacco F. Deregulated cytokine network and defective Th1 immune response in multiple myeloma. Clin Exp Immunol. 2001;125:190-197.
62. Younes H, Leleu X, Hatjiharissi E. et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007;13:3771-3775.
63. Wrobel T, Mazur G, Wolowiec D, Jazwiec B, Sowinska E, Kuliczkowski K. sVE-cadherin and sCD146 serum levels in patients with multiple myeloma. Clin Lab Haematol. 2006;28:36-39.
64. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol. 2003;170: 1136-1140.
65. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3:409-417.
66. Gollob JA, Mier JW, Veenstra K, et al. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res. 2000;6:1678-1692.
67. Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood. 2006;107:4650-4657.